Safety and immunogenicity of BNT162b2 vaccine in children with acute leukaemia: results and perspectives of an open-label, two-centre, phase 1/2 trial with dose finding study

Vaccine 2026 Open access

Read full text
Authors: Fanny Alby-Laurent, Amani Ouedrani, Pierre Jateau, Marion Strullu, Anouk Walter-Petrich, Chaima Mrad, Audrey Guilmatre, Maxime Ferreboeuf, Anne-France Ray-Lunven, Florentia Kaguelidou, Odile Launay, Lucienne Chatenoud
+3 more Laurence Morand-Joubert, Sylvie Chevret, Arnaud Petit
DOI: 10.1016/j.vaccine.2025.128130
Cited by: 2
References: 23

Abstract

Background . COVID-19 can be severe in children with acute leukaemia (AL), significantly delaying chemotherapy. This is the first study to address the safety and immunogenicity of BNT162b2 in children with AL. Methods: The PACIFIC trial ( NCT04969601 ) was a phase 1/2 dose-finding study in children aged

Fields of Study & Subjects

Acute Lymphoblastic Leukemia research Immunotherapy and Immune Responses CAR-T cell therapy research

Publication details

Journal / source
Vaccine
Publisher
Elsevier BV
Volume
74
Pages
128130–128130
Publication date
7 January 2026
Language
EN